We consider that deletion of PTPN22 remains a viable strategy for improving cancer immunotherapies such as ACT, however, careful consideration needs to be given to the differentiation state of the targeted T cells, in order to balance short-term augmented effector function with longer-term protection. The gene discussed is PTPN22; the disease is cancer.